Lirum Therapeutics to Present Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against Adult and Pediatric IGF-Related Cancers, at the 2024 AACR Annual Meeting
April 04, 2024 11:30 ET
|
Lirum Therapeutics, Inc.
New York, NY, April 04, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (Lirum), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced...
Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against IGF-Related Cancers, Accepted for Presentation at the 2024 ESMO Sarcoma and Rare Cancers Congres
March 14, 2024 08:00 ET
|
Lirum Therapeutics, Inc.
New York, NY, March 14, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases,...
Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, at the 2024 ESMO Targeted Anticancer Therapies Congress; Highlighting LX-101’s Potential in IGF-1R Prominent Cancers
February 26, 2024 08:00 ET
|
Lirum Therapeutics, Inc.
New York, NY, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases,...
Lirum Therapeutics Participates in the 13th Annual LifeSci Partners Corporate Access Event
January 09, 2024 16:11 ET
|
Lirum Therapeutics, Inc.
New York, NY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases,...
Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against Pediatric Sarcomas
October 31, 2023 13:27 ET
|
Lirum Therapeutics, Inc.
New York, NY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today...
Lirum Therapeutics to Present at the 2023 ThinkEquity Conference
October 19, 2023 08:00 ET
|
Lirum Therapeutics, Inc.
New York, NY, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases,...
Lirum Therapeutics Announces Closing of $7 Million Private Placement of Common Stock
February 08, 2023 15:03 ET
|
Lirum Therapeutics, Inc.
New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (the “Company” or “Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating...